Literature DB >> 20191487

Development and validation of a case ascertainment tool for ankylosing spondylitis.

Michael H Weisman1, Lan Chen, Daniel O Clegg, John C Davis, Robert W Dubois, Pamela E Prete, Laurie M Savage, Laura Schafer, Maria E Suarez-Almazor, Hsing-Ting Yu, John D Reveille.   

Abstract

OBJECTIVE: Ankylosing spondylitis (AS) diagnosis is often delayed. The availability of effective biologic agents for treating AS has increased the importance of early diagnosis. We tested questions derived from a comprehensive literature review and an advisory board in a case-control study designed to identify patients with AS from among patients with chronic back pain (CBP).
METHODS: Question items were cognitively tested among patients with AS, and then in case-control studies for validation and creation of a scoring algorithm and question item reduction. AS cases were recruited from a known database, and CBP subjects (controls) were recruited from clinics, employers, and from the SpineUniverse Web site. We used individual question items in a multivariate framework to discriminate between people with and without AS.
RESULTS: Forty-three questions yielded 24 items for analyses; 12 of these were entered into a multivariate regression model. Individual items yielded odds ratios ranging from 0.07 to 30.31. Question items with a significant positive relationship to AS included male sex, neck or hip pain/stiffness, longer pain duration, decreased pain/stiffness with daily physical activity, pain relief within 48 hours of nonsteroidal antiinflammatory drugs, and diagnosis of iritis. The tool demonstrated a sensitivity of 67.4 and a specificity of 94.6. The tool was developed from clinically and radiologically diagnosed AS cases and therefore is designed to distinguish AS cases among CBP subjects. In addition, approximately 54% of the AS cases in the study were treated with biologic agents, which may impact questionnaire responses.
CONCLUSION: This tool can identify undiagnosed patients with AS and, potentially, those at an earlier stage in their disease course.

Entities:  

Mesh:

Year:  2010        PMID: 20191487     DOI: 10.1002/acr.20009

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  8 in total

Review 1.  Early axial spondyloarthritis.

Authors:  Robert A Colbert
Journal:  Curr Opin Rheumatol       Date:  2010-09       Impact factor: 5.006

2.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 10 Patient information].

Authors:  U Kiltz; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

Review 3.  Diagnosis and classification in spondyloarthritis: identifying a chameleon.

Authors:  Astrid van Tubergen; Ulrich Weber
Journal:  Nat Rev Rheumatol       Date:  2012-03-27       Impact factor: 20.543

Review 4.  Referral strategies for early diagnosis of axial spondyloarthritis.

Authors:  Martin Rudwaleit; Joachim Sieper
Journal:  Nat Rev Rheumatol       Date:  2012-04-10       Impact factor: 20.543

5.  Epidemiology of spondyloarthritis in North America.

Authors:  John D Reveille
Journal:  Am J Med Sci       Date:  2011-04       Impact factor: 2.378

Review 6.  The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States.

Authors:  John D Reveille; Michael H Weisman
Journal:  Am J Med Sci       Date:  2013-06       Impact factor: 2.378

7.  The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10.

Authors:  Michael H Weisman; James P Witter; John D Reveille
Journal:  Ann Rheum Dis       Date:  2012-07-11       Impact factor: 19.103

8.  Development and test-retest reliability of a screening tool for axial spondyloarthritis.

Authors:  Divya Shridharmurthy; Kate L Lapane; Sara Khan; Esther Yi; Jonggyu Baek; Jonathan Kay; Shao-Hsien Liu
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.